SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

PINOTTI, Mirko
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.898
AS - Asia 8.201
EU - Europa 4.973
SA - Sud America 1.306
AF - Africa 126
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 31.529
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.566
SG - Singapore 3.297
CN - Cina 2.444
BR - Brasile 1.100
IT - Italia 1.058
DE - Germania 1.055
UA - Ucraina 764
HK - Hong Kong 760
TR - Turchia 504
GB - Regno Unito 494
VN - Vietnam 480
FI - Finlandia 342
PL - Polonia 281
RU - Federazione Russa 243
SE - Svezia 201
ID - Indonesia 185
CA - Canada 163
MX - Messico 146
FR - Francia 143
IN - India 133
AR - Argentina 93
BE - Belgio 79
JP - Giappone 76
NL - Olanda 67
BD - Bangladesh 66
ZA - Sudafrica 66
ES - Italia 55
IQ - Iraq 38
EC - Ecuador 37
CZ - Repubblica Ceca 36
AT - Austria 28
UZ - Uzbekistan 28
LT - Lituania 21
IR - Iran 20
CO - Colombia 17
CH - Svizzera 16
KR - Corea 16
PK - Pakistan 16
IL - Israele 15
KE - Kenya 15
PT - Portogallo 15
VE - Venezuela 15
MY - Malesia 14
AU - Australia 13
MA - Marocco 13
RO - Romania 13
PE - Perù 12
AE - Emirati Arabi Uniti 11
DK - Danimarca 11
GE - Georgia 11
NO - Norvegia 11
PY - Paraguay 11
JO - Giordania 10
SA - Arabia Saudita 10
TW - Taiwan 9
IE - Irlanda 8
UY - Uruguay 8
AZ - Azerbaigian 7
CL - Cile 7
CR - Costa Rica 6
KZ - Kazakistan 6
TN - Tunisia 6
AL - Albania 5
DZ - Algeria 5
NP - Nepal 5
TH - Thailandia 5
BG - Bulgaria 4
BO - Bolivia 4
BY - Bielorussia 4
KG - Kirghizistan 4
LA - Repubblica Popolare Democratica del Laos 4
LU - Lussemburgo 4
NG - Nigeria 4
OM - Oman 4
SN - Senegal 4
AF - Afghanistan, Repubblica islamica di 3
DO - Repubblica Dominicana 3
EG - Egitto 3
EU - Europa 3
GA - Gabon 3
GT - Guatemala 3
KH - Cambogia 3
KW - Kuwait 3
NZ - Nuova Zelanda 3
QA - Qatar 3
XK - ???statistics.table.value.countryCode.XK??? 3
BH - Bahrain 2
BW - Botswana 2
GR - Grecia 2
HN - Honduras 2
HU - Ungheria 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
NI - Nicaragua 2
PA - Panama 2
PH - Filippine 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
Totale 31.506
Salva come PNG Salva come JPEG
Città #
Singapore 1.839
Ashburn 1.494
Fairfield 1.429
Woodbridge 1.423
Dallas 1.259
Chandler 991
Houston 947
Santa Clara 916
Beijing 845
Jacksonville 814
Hong Kong 745
Ann Arbor 719
Seattle 614
Wilmington 557
Cambridge 474
Ferrara 392
Munich 317
Izmir 307
New York 296
Los Angeles 287
Warsaw 272
Nanjing 256
Princeton 232
Boardman 159
Ho Chi Minh City 158
Shanghai 155
Milan 149
Jakarta 146
Helsinki 139
San Diego 133
São Paulo 110
Dearborn 109
Hanoi 106
Bremen 105
Mexico City 97
Nanchang 84
Shenyang 73
Brussels 71
London 68
Tianjin 66
Brooklyn 63
Falls Church 60
Toronto 58
Jiaxing 57
The Dalles 56
Tokyo 56
Redwood City 54
Montreal 53
Hefei 51
Changsha 49
Chicago 48
Moscow 48
Buffalo 47
Denver 47
Orem 46
Atlanta 45
Hebei 45
Jinan 42
Frankfurt am Main 41
Poplar 41
Chennai 39
Johannesburg 39
Rio de Janeiro 39
Turku 39
San Mateo 37
Falkenstein 36
Mountain View 35
Bologna 34
Phoenix 34
Stockholm 34
Dong Ket 33
Guangzhou 32
Kunming 30
Norwalk 30
Curitiba 29
Des Moines 28
Nuremberg 28
Belo Horizonte 27
San Francisco 26
Auburn Hills 24
Ningbo 24
Zhengzhou 24
Brno 23
Columbus 23
Manchester 23
Ankara 22
Tashkent 22
Campinas 21
Da Nang 20
Padova 20
Porto Alegre 20
Washington 19
Brasília 18
Boston 17
Orange 17
Charlotte 16
Monmouth Junction 16
Paris 16
Amsterdam 15
Baghdad 15
Totale 21.404
Salva come PNG Salva come JPEG
Nome #
1,3,8-Triazaspiro[4.5]decane Derivatives Inhibit Permeability Transition Pores through a FO-ATP Synthase c Subunit Glu119-Independent Mechanism That Prevents Oligomycin A-Related Side Effects 946
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency 262
AN EXON-SPECIFIC U1 SMALL NUCLEAR RNA (snRNA) STRATEGY TO CORRECT SPLICING MUTATIONS ASSOCIATED TO HEMOPHILIA B 258
Regulation of a strong F9 cryptic 5'ss by intrinsic elements and by combination of tailored U1snRNAs with antisense oligonucleotides 250
An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes 249
An exon-specific U1snRNA induces a robust factor IX activity in mice expressing multiple human FIX splicing mutants 243
Exploring Splicing-Switching Molecules For Seckel Syndrome Therapy 240
Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth 235
Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings 231
A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates 215
Molecular Basis and Therapeutic Strategies to Rescue Factor IX Variants That Affect Splicing and Protein Function 210
Stimulation of P2 (P2X7) receptors in human dendritic cells induces the release of tissue factor-bearing microparticles. 208
U1-snRNA-mediated rescue of mRNA processing in severe factor VII deficiency 207
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 204
Nuove strategie per la veicolazione di acidi nucleici: nanosistemi cationici a matrice lipidica 201
VITAMIN K-INDUCED MODIFICATION OF COAGULATION PHENOTYPE IN VKORC1 HOMOZYGOUS DEFICIENCY 200
Activation of a cryptic splice site in a potentially lethal coagulation defect accounts for a functional protein variant 200
U1snRNA-mediated rescue of mRNA processing in severe factor VII deficiency 198
Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker? 194
Cationic lipid nanosystems as carriers for nucleic acids 192
Attività sulla emostasi di alcune piante della medicina tradizionale indiana 191
Chronic sleep deprivation markedly reduces coagulation factor VII expression 191
Transposon-mediated Generation of Cellular and Mouse Models of Splicing Mutations to Assess the Efficacy of snRNA-based Therapeutics 191
An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects 189
Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile 187
Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death 187
Mutation pattern in clinically asymptomatic coagulation factor VII deficiency 184
Asymptomatic carriership of factor V Leiden and genotypes of the fibrinogen gene cluster 183
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A 183
Effective hemostasis during minor surgery in a case of hereditary combined deficiency of vitamin K-dependent clotting factors 182
The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X 182
Tailoring the CRISPR system to transactivate coagulation gene promoters in normal and mutated contexts 181
Molecular bases of type II protein S deficiency: the I203-D204 deletion in the EGF4 domain alters GLA domain function 179
Membrane binding and anticoagulant properties of protein S natural variants 179
A unique exon specific U1snRNA rescues different haemophilia B - causing splicing-defective factor IX variants in mice 178
The carboxyl-terminal region is not essential for secreted and functional levels of coagulation factor X 178
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations 178
Evidence for an overlapping role of clock and npas2 transcription factors in liver circadian oscillators 177
Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity 176
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation 175
The dominant-negative von Willebrand factor gene deletion p.P1127-C1948delinsR: Molecular mechanism and modulation 174
FXIII levels and genotypes in myocardial infarction: a potential novel prognostic biomarker? 173
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glul02Lys) in the second EGF‐like domain 171
The factor V Glu1608Lys mutation is recurrent in familial thrombophilia 171
Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency 169
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 169
Circadian rhythms in mouse blood coagulation 168
Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis 168
Ribosome readthrough accounts for secreted full-length factor IX in hemophilia B patients with nonsense mutations 168
Cationic lipid nanosystems as carriers for nucleic acids 167
Temporal variations of coagulation factor VII activity in mice are influenced by lighting regime 166
Variation of factor VII 140s and 170s loops in fishes: evolutionary aspects and comparison with mutations found in FVII deficiency 165
Residual factor VII activity and different hemorrhagic phenotypes in CRM+ factor VII deficiencies (Gly331Ser and Gly283Ser) 164
Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation 164
Exon-specific U1 snRNAs improve ELP1 exon 20 definition and rescue ELP1 protein expression in a familial dysautonomia mouse model 163
A naturally occurring mutation in ATP synthase subunit c is associated with increased damage following hypoxia/reoxygenation in STEMI patients 162
Altered mRNA processing and FVIII biosynthesis/function as determinants of phenotype variability in the frequent Arg2016Trp Haemophilia A patients. 161
Correction of aberrant splicing causing haemophilia B through the combination of compensatory U1snRNAs and antisense oligonucleotides 160
Factor VII mutant V154G models a zymogen-like form of factor VIIa 159
Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity 157
Characterization of anti-coagulant properties of prenylated coumarin ferulenol. 156
Molecular defects in CRM+ factor VII deficiencies: modelling of missense mutations in the catalytic domain of FVII 155
Aberrant splicing reverts a potentially lethal coagulation deficiency caused by a +1g/t splicing mutation 154
The complete impairment of factor VII gene expression by the IVS6+1g/t mutation is compatible with a severe but not lethal bleeding disorder 154
Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity 153
Nanosistemi lipidici per la veicolazione di acidi nucleici 153
Acute Coronaric Syndroms and FVII polymorphisms: different effects in the same gene 153
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 153
Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease 152
Molecular mechanisms of FVII deficiency: Expression of mutations clustered in the IVS7 donor splice site of factor VII gene 152
Combined effect of hemostatic gene polymorphisms and the risk of myocardial infarction in patients with advanced coronary atherosclerosis 151
Modulation of factor VII levels by intron 7 polymorphisms: Population and in vitro studies 150
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 150
A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B 149
Disease-causing variants of the conserved+2T of 5 ' splice sites can be rescued by engineered U1snRNAs 148
A very rare simultaneous presence of a ring chromosome 13 and a splicing site mutation on Factor X gene 146
Activation of Endoplasmic Reticulum Stress and Unfolded Protein Response in Congenital Factor VII Deficiency 145
Long-chain cationic derivatives of PTA (1,3,5-triaza-7-phosphaadamantane) as new components of potential non-viral vectors 144
Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma 143
Rescue of coagulation factor VII function by the U1+5A snRNA 143
Impaired prothrombinase activity of factor X Gly381 Asp results in severe familial CRM+ FX deficiency 142
Detection and characterization of polymorphic markers in the factor-VII gene. 142
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies 141
Next-generation sequencing and recombinant expression characterized aberrant splicing mechanisms and provided correction strategies in factor VII deficiency 141
Rescue of missense and splicing mutations in Haemophilia A by a unique Exon Specific U1snRNA 140
Association of the homozygous nonsense mutation R402X in coagulation factor VII with asymptomatic phenotype 140
Non-conventional therapeutic strategies for inherited disorders oh hemostasis 138
The carboxyl-terminal region of human coagulation factor X as a novel naturally-occuring linker for fusion strategies 138
Contribution of factor VII genotype to activated FVII levels: Differences in genotype frequencies between northern and southern European populations 137
Cationic nanostructured lipid carrier (NLC) and monoolein aqueous dispersions (MAD) as potential carriers for nucleic acids 137
RNA-based therapeutic approaches for coagulation factor deficiencies 137
Gentamicin induces sub-therapeutic levels of coagulation factor VII in patients with nonsense mutations 137
Rescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA 137
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics 137
Polymorphic changes in the 5' flanking region of factor VII have a combined effect on promoter strength 136
FXIII Levels in Myocardial Infarction: a Potential Novel Prognostic Biomarker? 136
CRISPR activation on coagulation F7 or F8 promoters potentiate trascriptional activity in the normal and mutated gene context 136
Management of Kidney Transplantation in a Factor VII-Deficient Patient: Case Report 136
The Gly331Ser mutation in factor VII in Europe and the Middle East 135
Major differences in bleeding symptoms between factor VII deficiency and hemophilia B 135
Totale 17.875
Salva come PNG Salva come JPEG
Categoria #
all - tutte 153.381
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.077
Totale 154.458
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.901 0 0 0 0 0 242 231 330 131 454 366 147
2021/20222.248 137 262 114 73 113 104 112 106 80 187 185 775
2022/20232.359 261 184 73 301 409 315 135 179 276 15 128 83
2023/20241.269 110 140 79 45 79 210 50 77 36 48 40 355
2024/20255.698 175 117 507 179 696 710 172 233 886 585 781 657
2025/20269.198 1.530 905 1.944 2.153 2.378 288 0 0 0 0 0 0
Totale 32.028